Insulet Co. (NASDAQ:PODD) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Insulet Co. (NASDAQ:PODD) have earned an average recommendation of “Moderate Buy” from the sixteen ratings firms that are presently covering the company, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation and thirteen have assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $250.33.

A number of research analysts have commented on PODD shares. Robert W. Baird upgraded Insulet from a “neutral” rating to an “outperform” rating and increased their price objective for the company from $180.00 to $238.00 in a research report on Thursday, December 21st. Stifel Nicolaus raised their price target on Insulet from $163.00 to $208.00 and gave the company a “hold” rating in a report on Monday, February 5th. Barclays dropped their price objective on Insulet from $214.00 to $213.00 and set an “equal weight” rating for the company in a report on Monday, February 26th. Piper Sandler reduced their target price on shares of Insulet from $250.00 to $230.00 and set an “overweight” rating on the stock in a research note on Friday, February 23rd. Finally, JPMorgan Chase & Co. boosted their price target on shares of Insulet from $190.00 to $225.00 and gave the stock an “overweight” rating in a research note on Friday, February 23rd.

Insulet Stock Performance

Insulet stock opened at $175.22 on Friday. The stock has a 50-day simple moving average of $176.72 and a 200 day simple moving average of $178.57. The stock has a market capitalization of $12.27 billion, a price-to-earnings ratio of 60.21, a P/E/G ratio of 3.19 and a beta of 0.98. The company has a quick ratio of 2.62, a current ratio of 3.51 and a debt-to-equity ratio of 1.86. Insulet has a 12-month low of $125.82 and a 12-month high of $335.91.

Insulet (NASDAQ:PODD) last announced its earnings results on Thursday, February 22nd. The medical instruments supplier reported $1.40 earnings per share for the quarter, topping analysts’ consensus estimates of $0.67 by $0.73. Insulet had a net margin of 12.16% and a return on equity of 32.19%. The company had revenue of $509.80 million during the quarter, compared to the consensus estimate of $461.26 million. During the same period in the previous year, the firm posted $0.55 earnings per share. The company’s revenue was up 37.9% on a year-over-year basis. On average, research analysts anticipate that Insulet will post 3.08 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Insulet news, Director Shacey Petrovic sold 11,609 shares of the business’s stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $162.92, for a total value of $1,891,338.28. Following the completion of the transaction, the director now directly owns 2,567 shares of the company’s stock, valued at $418,215.64. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.90% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the stock. Capital Research Global Investors raised its holdings in shares of Insulet by 19.7% during the fourth quarter. Capital Research Global Investors now owns 9,476,623 shares of the medical instruments supplier’s stock worth $2,056,255,000 after acquiring an additional 1,556,455 shares during the period. Vanguard Group Inc. raised its stake in shares of Insulet by 0.4% in the 4th quarter. Vanguard Group Inc. now owns 8,029,608 shares of the medical instruments supplier’s stock valued at $1,742,264,000 after purchasing an additional 29,387 shares during the period. Clearbridge Investments LLC raised its stake in shares of Insulet by 38.8% in the 1st quarter. Clearbridge Investments LLC now owns 1,696,822 shares of the medical instruments supplier’s stock valued at $452,016,000 after purchasing an additional 474,545 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Insulet by 55.4% in the first quarter. Geode Capital Management LLC now owns 1,486,725 shares of the medical instruments supplier’s stock valued at $473,166,000 after purchasing an additional 529,926 shares in the last quarter. Finally, Moneta Group Investment Advisors LLC boosted its position in shares of Insulet by 101,333.5% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 1,300,377 shares of the medical instruments supplier’s stock worth $382,818,000 after buying an additional 1,299,095 shares during the period.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.